Abraxane News
Drugs
> Abraxane Abraxane News is an EIN News Service for health professionals. Constantly updated news and information about health.
- Press conference highlights emerging treatments in pancreatic cancer 18 Nov 2009 09:58 GMT
... the University of Pennsylvania. The currently available treatment is gemcitabine, which is sold as Gemzar ... Avastin by Genentech, which is an anti-angiogenesis drug designed to starve cancerous tumors of the ... Lilly and Company, and nab-paclitaxel, sold as Abraxane by Abraxis Bioscience, are clinically available treatments. ...
- 4 Platform Drugmakers to Invest In 24 Nov 2009 20:53 GMT
... pool or '70s night at the disco. Drugmakers are using the same patented technology -- ... population that sometimes has trouble taking daily medication. also has a partnership with Johnson & ... The company already had one drug approved, Abraxane, which uses the company's (nanoparticle-albumin bound) technology ...
- Genasense Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma 20 Nov 2009 13:44 GMT
... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane (paclitaxel protein-bound particles for injectable suspension [albumen ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Emerging Therapies in Pancreatic Cancer Show Promise 17 Nov 2009 19:52 GMT
... the University of Pennsylvania. The currently available treatment is gemcitabine, which is sold as Gemzar ... Avastin by Genentech, which is an anti-angiogenesis drug designed to starve cancerous tumors of the ... Lilly and Company, and nab-paclitaxel, sold as Abraxane by Abraxis Bioscience, are clinically available treatments. ...
- www.standoutstocks.com: Stocks That Stand Out For Nov. 20th, 2009 Are RFMD, GETA, CLDS, HESG 20 Nov 2009 18:59 GMT
... Nov 20, 2009 (M2 PRESSWIRE via COMTEX) -- www.Standoutstocks.com: Stocks ... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Genasense® Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma 23 Nov 2009 15:40 GMT
... Data Presented at International Melanoma Conference in Berlin Results ... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane® (paclitaxel protein-bound particles ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Genasense® Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma 23 Nov 2009 16:12 GMT
... Data Presented at International Melanoma Conference in Berlin Results ... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane® (paclitaxel protein-bound particles ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma 20 Nov 2009 13:41 GMT
... Data Presented at International Melanoma Conference in Berlin Results ... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Genasense® Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma 20 Nov 2009 13:46 GMT
... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane (paclitaxel protein-bound particles for injectable suspension [albumen ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Research and Markets: Cancer Therapies - Global Market Opportunities 19 Nov 2009 14:11 GMT
... system's screening systems, and abilities. Standard cancer treatments such as chemotherapy, radiation therapy, surgery, given ... as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity. ... -- Avexa to Acquire Progen Pharmaceuticals -- ABRAXANE Gains Marketing Approval in Korea, Australia and ...
- Research and Markets: Cancer Therapies - Global Market Opportunities (BIZ) 19 Nov 2009 13:55 GMT
... system's screening systems, and abilities. Standard cancer treatments such as chemotherapy, radiation therapy, surgery, given ... as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity. ... Therapy -- Hormonal Therapy -- Immunotherapy -- ABRAXANE Gains Marketing Approval in Korea, Australia and ...
- Check Us Out!!! Sign Up Now For Our Free Newsletter!! BRGO,QSAP,XCEL,XMDC,MTVO,GETA 20 Nov 2009 18:59 GMT
... Check Us Out!!! Sign Up Now For Our Free ... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- OTC ADVISORS, LLC: Huge Stock News Alert On - (OTCBB:BRGO) - (OTCBB:GETA) - (OTCBB:ARTS) 20 Nov 2009 16:59 GMT
... OTC ADVISORS, LLC: Huge Stock News Alert On - ... focused on delivering innovative products for the treatment of patients with cancer. Two major programs ... effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) ...
- Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma (BIZ) 20 Nov 2009 13:40 GMT
... (Temodar ), the most commonly used anticancer drug for melanoma, and Abraxane (paclitaxel protein-bound particles for injectable suspension [albumen ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
- Genta announces preliminary results from study of Genasense Injection for advanced melanoma 20 Nov 2009 14:57 GMT
... Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane (paclitaxel protein-bound particles for injectable suspension [albumen ... confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
nytimes.com:
ap.org:
bbc.co.uk:
reuters.com:
msnbc.msn.com:
healthday.com: